Lymphoma patients in India now have unprecedented access to revolutionary CAR-T cell therapy, with indigenous treatments offering 70-83% response rates at costs 80% lower than international alternatives, transforming advanced blood cancer care across the country. TL;DR Dr.Bh arat Patodiya connects lymphoma patients with India's leading CAR-T centers, offering comprehensive evaluation and treatment coordination at ₹30-50 lakhs versus ₹3-4 crores internationally [1] India's in